BioInvent International
22.30 SEK
-0.45 %
Less than 1K followers
BINV
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for BioInvent International
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 93.7 | 147.4 | 19.4 | 326.1 | 71.5 | 44.7 | 226.5 |
| growth-% | 57.2 % | -86.8 % | 1,582.5 % | -78.1 % | -37.5 % | 406.8 % | |
| EBITDA | -126.2 | -63.5 | -263.7 | -36.2 | -353.2 | -451.8 | -331.8 |
| EBIT | -137.8 | -75.5 | -278.4 | -50.9 | -369.9 | -471.1 | -351.7 |
| Profit before taxes | -138.6 | -76.3 | -278.4 | -42.5 | -330.1 | -429.2 | -332.5 |
| Net income | -138.6 | -76.3 | -278.4 | -42.5 | -330.3 | -429.4 | -332.9 |
| EPS | -6.78 | -1.94 | -5.14 | -0.69 | -5.02 | -6.53 | -5.06 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | -134.7 % | -43.1 % | -1,360.6 % | -11.1 % | -494.2 % | -1,010.9 % | -146.5 % |
| EBIT-% | -147.1 % | -51.2 % | -1,436.0 % | -15.6 % | -517.7 % | -1,054.1 % | -155.3 % |
| ROE | -81.8 % | -10.3 % | -20.4 % | -2.6 % | -25.2 % | -48.5 % | -59.7 % |
| ROI | -61.3 % | -9.5 % | -19.2 % | -2.5 % | -23.6 % | -43.4 % | -49.6 % |